Weekly Stock Review – Top 4 stocks you should be monitoring!

Top 4 stocks you should be monitoring!

IT has been a volatile week for stocks.  However, some of The companies have shown extremely good results during last few days, here are some of them and why investors should monitor them closely:

  • Walt Disney / Ticker: DIS

Shares of Walt Disney surged more than 14% on Friday, following the entertainment titan’s investor day. Disney announced that its massively popular streaming service, Disney+, now has more than 86 million subscribers, which is incredible, because previously they expected to have this number of subscribers by 2024. But it’s not all. Very soon highly anticipated TV shows like WandaVision (January 15), Loki (May 2021) and others are airing, and we suspect these shows will bring in even more customers for the streaming giant.

  • Virgin Galactic / Ticker: SPCE

Virgin Galactic was up more than 15% on Monday in anticipation of its upcoming test flight, which could take place this weekend. Virgin Galactic is an American spaceflight company within the Virgin Group. It is developing commercial spacecraft and aims to provide suborbital spaceflights to space tourists and suborbital launches for space science missions.  If all goes well, it will be the first of two test flights before Richard Branson takes off on Virgin Galactic’s first commercial flight. SPCE market cap has gone over 7 billion and it has shown pretty good results during the last few months as well.

  • Palantir Technologies / Ticker: PLTR

Palantir Technologies rallied 21% on Monday after reportedly securing a 3-year contract with the FDA. Palantir Technologies is a public American software company that specializes in big data analytics. According to sources, the three-year deal is worth $44.4 million and will allow the FDA’s Center for Drug Evaluation and Research and the Oncology Center of Excellence to use Palantir software to integrate and analyze vast amounts of data regarding Covid-19 Vaccine and other drugs. Palantir has shown crazy gains during the last few months.

  • Editas Medicine / Ticker: EDIT

Editas Medicine, a gene-editing company, has gained more than 70% during the last 5 days. On Wednesday, it filed an Investigational New Drug. Last weekend, the company presented preclinical data on EDIT-301 to treat sickle cell disease and beta-thalassemia. The company also presented on editing human induced pluripotent stem cell-derived NK cells as allogeneic engineered cells for oncology treatments. The price has skyrocketed after the announcements. Pharmaceutical stocks have been performing very well lately due to rise in interest of investors because of the Covid-19 vaccine.

Want to know how to start investing in Cryptocurrencies and Stocks? Click here and get more information about the top investing platform available.

Buy crypto instantly on Uphold